By Justin Wingerter Staff Writer jwingerter@oklahoman.com
U.S. Rep. Markwayne Mullin, who sits on a subcommittee with oversight of the Food and Drug Administration, says his six-figure investment in an Australian pharmaceutical company does not constitute a conflict of interest because the FDA has no oversight of that company.
But the company in question, Innate Immunotherapeutics, says otherwise.
"Innate Immunotherapeutics Limited is pleased to confirm it has received clearance from the U.S. Food and Drug Administration for the company's investigational new drug (IND) application lodged last month," Innate wrote in a news release June 21.
A month after Innate was given that clearance from the FDA, Mullin was asked during a conference call with Oklahoma reporters about his Jan.
Read more on NewsOK.com
via NewsOK.com RSS - politics >> !The Oklahoman